Trials to learn the safety of vaccines to prevent the spread of the Ebola virus are moving as fast as possible in the United States and in Great Britain, as public health officials on both sides of the Atlantic scramble to contain the worst-ever outbreak of the disease.
Trials to learn the safety of vaccines to prevent the spread of the Ebola virus are moving as fast as possible in the United States and in Great Britain, as public health officials on both sides of the Atlantic scramble to contain the worst-ever outbreak of the disease.
Meanwhile, the question of who will pay for to develop and distribute doses of the vaccine has not been answered, but published reports suggest wealthier countries, aid groups, the military, or some combination may foot the bill, which will bring a rethinking of how to create better incentives to fund developing of life-saving prevention and cures for diseases that threaten poor nations first, with less obvious commercial value.
As reported in the current issue of Evidence-Based Immunology and Infectious Disease, a news publication of The American Journal of Managed Care, the 2 leading vaccine candidates are a vaccine being co-developed by the National Institutes of Health and GlaxoSmithKline (GSK), and a vaccine being developed by a small US drugmaker, NewLink Genetics, which is working with the University of Maryland on a vaccine that was originally developed for public health agencies in Canada.
A meeting in Geneva end of September—convened by the World Health Organization (WHO)—brought together scientists, public health officials, and individuals from the industry and regulatory agencies (including from the FDA and the European Medicines Agency), who emphasized the need to expedite phase 1 trials and share the resulting data. This would allow for faster initiation of phase 2 trials.
Phase 2a trials, which determine dose levels, are proposed to be conducted in Africa outside the infection zone, and would be conducted in parallel with phase 2b trials in exposed populations, to determine the efficacy of the vaccine. Many reports have surfaced of volunteers, including healthcare workers, receiving doses of vaccine as part of these trials.
Reports have indicated that the first groups to eventually receive vaccines will be healthcare workers exposed to patients in clinics and hospitals, family members of patients, and people who cleanse and bury deceased patients. According to EBIID, a follow-up meeting of the WHO is planned for early next month, when preliminary results from the phase 1 trials will be available, to decide the future course of action.
Whichever vaccine reaches the infection zone first matters less than changing the way the world approaches their development going forward, a leading public health expert told USA Today.
"The political bet is that the US and World Health Organization have been so embarrassed and burned by this event that they will be willing to change the way they do business," said Professor Lawrence Gostin of the Georgetown University Law School, who studies global health issues. "To me, Ebola is a game changer. All the things we thought about in terms of research priorities and development of drugs and vaccines need to be rethought."
Around the Web
Racing to Contain Ebola After Early Failures
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen